GlassScriptPhysician profile
Martin Zamora
NPI 1801986583
$44,390.85
in general payments reported to CMS, 2019-2025
26 companies · $3,593 in 2025
The $3,593 reported for 2025 was more than what 91% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $4,822 · 2021: $3,393 · 2022: $2,527 · 2023: $4,545 · 2024: $5,757 · 2025: $3,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,640 · Food and Beverage: $2,991 · Consulting Fee: $2,924 · Travel and Lodging: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,640.00 |
| Food and Beverage | $2,990.79 |
| Consulting Fee | $2,923.75 |
| Travel and Lodging | $340.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $15,142.47 | 2019-2021 | |
| Kamada LTD. | $9,367.74 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $6,509.88 | 2019 | |
| Grifols Shared Services North America, INC. | $5,977.73 | 2019 | |
| Biotest Ag | $4,625.57 | 2022-2023 | |
| La Jolla Pharmaceutical Company | $988.39 | 2020-2025 | Giapreza |
| Abbvie INC. | $337.85 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.01 | 2022-2025 | Ofev |
| Atricure, INC. | $169.89 | 2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Allergan, INC. | $127.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2023 | Livtencity |
| Glaxosmithkline, LLC. | $117.93 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $108.24 | 2022 | |
| Genzyme Corporation | $102.57 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $90.91 | 2022 | |
| United Therapeutics Corporation | $50.13 | 2023 | Tyvaso |
| Vapotherm INC | $49.44 | 2023 | Vapotherm |
| Baxter Healthcare | $30.98 | 2023 | Hillrom - Life 2000 Ventilation System |
| Alcresta Therapeutics, INC. | $25.29 | 2023 | Relizorb |
| Astellas Pharma US INC | $24.78 | 2023 | Cresemba |
| Fisher & Paykel Healthcare INC | $24.22 | 2023 | Fisher & Paykel Healthcare |
| Intercept Pharmaceuticals, INC. | $22.88 | 2025 | |
| Masimo Corporation | $20.53 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.03 | 2024 | Nuzyra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Zamora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.